A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Clinical trial NCT02760602 · TERMINATED
Trial details
- NCT number
- NCT02760602
- Sponsor
- Eli Lilly and Company
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2017-05-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.